Ralitsa Kermedchieva

Dr. Ralitsa Kermedchieva


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2021 in Folia Medica
Verified
Journal Article
Open access
PDF file
RKRalitsa Kermedchieva
Ralitsa Kermedchieva
MKMarieta Konareva-Kostianeva
Marieta Konareva-Kostianeva
Vesela Todorova Mitkova-HristovaVesela Todorova Mitkova-Hristova
Vesela Todorova Mitkova-Hristova
MAMarin Atanassov
Marin Atanassov
Nina Staneva StoyanovaNina Staneva Stoyanova
Nina Staneva Stoyanova
Introduction: Filtration surgery is the most effective method of lowering intraocular pressure (IOP) in patients with insufficient medical control. It consists in facilitating the drainage of the intraocular fluid (IOF) from the anterior chamber to the subconjunctival space and subsequent lowering of IOP. The formation of filtration blebs (FB) and the processes of scarring occurring in the conjunctiva are of particular importance in glaucoma surgery. In many cases, the appearance of FB does not match the IOP values, and what causes the failure after trabeculectomy often remains unclear. Often, over time, there is a change in the structure of the FB, as fibrous tissue grows, which prevents the IOF drainage. Laser scanning in vivo confocal microscopy is a non-invasive study allowing the production of layered images at the microstructural level with high resolution of both the cornea and other structures of the anterior ocular surface. Aim: To evaluate the morphological structure and function of filtering blebs after trabeculectomy using in vivo confocal microscopy taking into account the type of implant and when the surgery was performed. Materials and methods: The study included 33 patients, 46 eyes with glaucoma. Twenty-six of the eyes had primary open-angle glaucoma (POAG), 18 eyes had pseudoexfoliative glaucoma and 2 eyes had juvenile glaucoma. All patients underwent trabeculectomy with fornix-based flap, and three of the eyes underwent retrabeculectomy. Mitomicyn C (MMC) was administered intraoperatively to all patients. The study of the filtering bleb was performed by in vivo confocal microscopy (CFM) (Heidelberg Retina Tomograph II (HRT II) /Rostock Cornea Module/ (Heidelberg Engineering GmbH, Heidelberg, Germany), the period from trabeculectomy and examination being from 1 year to 22 years. An Express implant was placed in 14 eyes, Ologen implant in 7 eyes, and 25 eyes had no implant placed. In the analysis of the morphological structure of the filtering blebs, three indicators were evaluated: the type of epithelium, the type of stroma, and blood vessels. Results: Statistical significance was established with regard to the function and morphological structure of the filtering bleb (p=0.009). Blebs with fine collagen mesh and dense collagen mesh demonstrate good function. In the case of blebs with insufficient function, those with a dense collagen network and hyper-reflective tissue predominated and there were no blebs with a fine collagen network, and in non-functioning blebs most common were those with a pronounced collagen network and hyper-reflective tissue. With regard to vascularization, we found that the functioning blebs in the shortest postoperative period were dominated by those with one blood vessel (stage 1) and there was no stage 3, with weak tortuosity, while in non-functioning blebs in the late postoperative period, there was moderate to severe vascularization and tortuosity (p=0.037), (p=0.043), (p=0.047), (p=0.021). The type of implant affects the tortuosity of the blood vessels of the filtering bleb (p=0.026). The blebs with Express implants show a slight tortuosity, followed by the blebs with Ologen implants. The highest percentage of highly kinked blood vessels occurred in blebs without an implant. Conclusions: In vivo confocal microscopy is an innovative method which allows visualization of the internal structure of the filtering blebs at a cellular level, giving us a new insight into the ongoing healing processes, premising the function of the filtering blebs after glaucoma surgery.

22 December 2025 in Vision
Verified
Journal Article
Open access
PDF file
IMIoanna Misheva
Ioanna Misheva
VDVesselin Daskalov
Vesselin Daskalov
DDDimitar Dzhelebov
Dimitar Dzhelebov
KIKalina Ilieva Ilieva
Kalina Ilieva Ilieva
RKRalitsa Kermedchieva
Ralitsa Kermedchieva
CGChristina Grupcheva
Christina Grupcheva
The aim of this study was to evaluate the performance and safety of T2769 (Thealoz® Total), a preservative-free eye drop combining 0.15% sodium hyaluronate, 3% trehalose, and 2.45% N-acetylaspartyl-glutamate (NAAGA), in contact lens wearers with dry eye symptoms and discomfort. This prospective, single-arm investigation enrolled 34 adult contact lens wearers with Ocular Surface Disease Index (OSDI) scores ≥ 18 and Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) scores ≥ 12. Patients instilled one drop of T2769 three to six times daily for 36 days. Performance assessments included CLDEQ-8, ocular discomfort and symptoms, OSDI, soothing sensation, and ocular signs. Safety assessments included adverse events (AEs), far BCVA, and ocular tolerance. CLDEQ-8 improved from the baseline at Day 36 (−12.6 ± 5.0; p < 0.001) and as early as D15, with similar improvements in ocular discomfort, OSDI, and total symptom score. Soothing sensation was judged important by 79.4% of patients at D36. Ocular surface staining, tear break-up time, and the Schirmer test improved at D15 and D36, while conjunctival hyperaemia improved in 82.4% of patients at D36. Two non-serious treatment-related AEs (photophobia and blurred vision) occurred in one patient. BCVA was unchanged, and tolerance was rated very satisfactory/satisfactory. In conclusion, T2769 was safe and effective for reducing contact lens-associated dry eyes and discomfort.

8 September 2023 in Bulgarian Review of Ophthalmology
Verified
Journal Article
Open access
PDF file
VDVesselin Daskalov
Vesselin Daskalov
RKRalitsa Kermedchieva
Ralitsa Kermedchieva
Introduction: Over the last decade, the surgical treatment of glaucoma has undergone evolution with the introduction of microimplants. Considered the gold standard until recently, the classic trabeculectomy, introduced by Cairns in 1968, was replaced by minimally invasive glaucoma surgery (MIGS). Aim: The purpose of this study is to present the efficacy of PreserFlo MicroShunt (Santen, Osaka, Japan) draining intraocular fluid into the subconjunctival space with the formation of a bleb, similar to classic trabeculectomy. Materials and Methods: A retrospective analysis was performed including patients with open-angle glaucoma after MIGS, with PreserFlo implantation and the administration of MMC: 0.4 mg/mL for 2 min, intraoperatively. A total of 43 patients (50 eyes) were included, of whom 22 men (51.16%) and 21 women (48.84%). The average age was 65.26 years (32–91 years). The implantations were carried out within the period 2020–2023, with a follow-up period of two years. Results: After the performed procedure, we reported the effectiveness of the PreserFlo in lowering intraocular pressure (IOP) with 82% of the cases having values </= 18 mmHg, with or without therapy, as well as success of the surgical treatment with similar results. Furthermore, a reduction in medication therapy was reported, with 91.3% not requiring such postoperatively during the follow-up period of 2 years, as well as a low rate of reoperation (15.2%). Conclusion: With its unique design, promising efficacy and minimal invasiveness during implantation, PreserFlo would be a good tool of choice in the treatment of open-angle glaucoma.